Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash & Equivalents (2017 - 2025)

Arcus Biosciences has reported Cash & Equivalents over the past 9 years, most recently at $222.0 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $222.0 million for Q4 2025, up 48.0% from a year ago — trailing twelve months through Dec 2025 was $222.0 million (up 48.0% YoY), and the annual figure for FY2025 was $222.0 million, up 48.0%.
  • Cash & Equivalents for Q4 2025 was $222.0 million at Arcus Biosciences, down from $238.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for RCUS hit a ceiling of $549.0 million in Q1 2022 and a floor of $127.0 million in Q4 2023.
  • Median Cash & Equivalents over the past 5 years was $212.0 million (2022), compared with a mean of $232.8 million.
  • Biggest five-year swings in Cash & Equivalents: soared 479.66% in 2021 and later plummeted 56.65% in 2023.
  • Arcus Biosciences' Cash & Equivalents stood at $148.0 million in 2021, then surged by 39.19% to $206.0 million in 2022, then tumbled by 38.35% to $127.0 million in 2023, then grew by 18.11% to $150.0 million in 2024, then skyrocketed by 48.0% to $222.0 million in 2025.
  • The last three reported values for Cash & Equivalents were $222.0 million (Q4 2025), $238.0 million (Q3 2025), and $248.0 million (Q2 2025) per Business Quant data.